Featured Market Report: Atopic Dermatitis (eczema) Forecast in 17 Major Markets
pharmafile | December 7, 2015 | Feature | Manufacturing and Production, Research and Development | Black Swan, eczema
Featured Market Report: Forecast Report on Atopic Dermatitis (eczema) in 17 Major Markets
Black Swan’s report on Atopic Dermatitis, also known as eczema, provides the current prevalent population for the common condition across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Canada, Australia, South Africa, Poland, Russia and China) split by gender and five-year age cohort.
The purchaser will find an overview of severity, location and IgE levels of Atopic Dermatitis, as well as a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity, all made available using data and information sourced from the proprietary Epiomic patient segmentation database.
Why buy?
- Gain the ability to quantify patient populations in global Atopic Dermatitis’s market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of Atopic Dermatitis and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Atopic Dermatitis’s prevalent population.
- Identify sub-populations within Atopic Dermatitis which require treatment.
- Gain an understanding of the specific markets that have the largest number of Atopic Dermatitis patients.
To view further details, or to buy, please click here.
The Pharmafile.com team is happy to provide you with any further information you may require in order to decide whether to purchase this or any of our listed Market Reports from our internationally-recognised research partners.
If you require any such advice or information, please do not hesitate contact us, and we will get back to you promptly.
Related Content
MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain …
UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy
Researchers at the University of California San Diego School of Medicine have identified a universal …
LEO Pharma’s delgocitinib hits main goals in moderate-to-severe chronic hand eczema
LEO Pharma has revealed new Phase 2b at the European Academy of Dermatology and Venereology …
